MX2021003574A - Composiciones y metodos para mejorar la entrega, tolerabilidad y eficacia de los peptidos y macrociclicos cationicos. - Google Patents

Composiciones y metodos para mejorar la entrega, tolerabilidad y eficacia de los peptidos y macrociclicos cationicos.

Info

Publication number
MX2021003574A
MX2021003574A MX2021003574A MX2021003574A MX2021003574A MX 2021003574 A MX2021003574 A MX 2021003574A MX 2021003574 A MX2021003574 A MX 2021003574A MX 2021003574 A MX2021003574 A MX 2021003574A MX 2021003574 A MX2021003574 A MX 2021003574A
Authority
MX
Mexico
Prior art keywords
defensin
formulations
compositions
deliverability
tolerability
Prior art date
Application number
MX2021003574A
Other languages
English (en)
Inventor
Dat Tran
Justin B Schaal
Patti Tran
Michael E Selsted
Original Assignee
The Univ Of Suthern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Suthern California filed Critical The Univ Of Suthern California
Publication of MX2021003574A publication Critical patent/MX2021003574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones para formulaciones de 0-defensina y/o un análogo de 0-defensina que son muy adecuadas para la administración parenteral. Tales les formulaciones proporcionan la 0-defensina y/o un análogo de 6-defensina en un tampón ligeramente ácido que incluye propilenglicol. Sorprendentemente, los inventores han descubierto que tal formulación aumenta la biodisponibilidad de una 0-defensina y/o un análogo de 0-defensina proporcionado por al menos un factor de 10 en relación con las soluciones salinas isotónicas convencionales, y que tales formulaciones mejoraron drásticamente la biodisponibilidad en sujetos humanos en relación con las soluciones salinas isotónicas convencionales a modelos animales. Los inventores también han descubierto que tales formulaciones exhiben ventajosamente baja viscosidad a altas concentraciones de péptidos, reduciendo el volumen de inyección permitiendo la esterilización por simple filtración.
MX2021003574A 2018-10-09 2019-10-09 Composiciones y metodos para mejorar la entrega, tolerabilidad y eficacia de los peptidos y macrociclicos cationicos. MX2021003574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743243P 2018-10-09 2018-10-09
PCT/US2019/055362 WO2020076925A1 (en) 2018-10-09 2019-10-09 Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides

Publications (1)

Publication Number Publication Date
MX2021003574A true MX2021003574A (es) 2021-08-27

Family

ID=70164024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003574A MX2021003574A (es) 2018-10-09 2019-10-09 Composiciones y metodos para mejorar la entrega, tolerabilidad y eficacia de los peptidos y macrociclicos cationicos.

Country Status (12)

Country Link
US (1) US20210346463A1 (es)
EP (1) EP3863607A4 (es)
JP (2) JP2022502472A (es)
KR (1) KR20210055792A (es)
CN (2) CN117379529A (es)
AU (1) AU2019356916B2 (es)
BR (1) BR112021006643A8 (es)
CA (1) CA3115770C (es)
IL (1) IL282199A (es)
MX (1) MX2021003574A (es)
SG (1) SG11202103073SA (es)
WO (1) WO2020076925A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240108702A1 (en) 2021-01-20 2024-04-04 The University Of Southern California Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection
WO2023097211A1 (en) * 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022829A1 (en) * 2001-03-30 2003-01-30 Wendy Maury Novel antiviral activities primate theta defensins and mammalian cathelicidins
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
CA2545034C (en) * 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
BR112013030874B8 (pt) * 2011-06-02 2021-09-14 Univ California Uso de uma theta-defensina ou análogo da mesma para tratar uma condição inflamatória crônica
US9217021B2 (en) * 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
WO2016059593A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of protein drugs and process for its preparation
US20170035845A1 (en) * 2015-08-07 2017-02-09 The Regents Of The University Of California Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression

Also Published As

Publication number Publication date
EP3863607A4 (en) 2022-07-06
BR112021006643A2 (pt) 2021-07-20
CN113164390A (zh) 2021-07-23
JP2023133565A (ja) 2023-09-22
US20210346463A1 (en) 2021-11-11
CA3115770A1 (en) 2020-04-16
CN117379529A (zh) 2024-01-12
CA3115770C (en) 2023-11-14
IL282199A (en) 2021-05-31
BR112021006643A8 (pt) 2022-12-06
AU2019356916B2 (en) 2022-12-01
KR20210055792A (ko) 2021-05-17
EP3863607A1 (en) 2021-08-18
JP2022502472A (ja) 2022-01-11
AU2019356916A1 (en) 2021-05-06
WO2020076925A1 (en) 2020-04-16
SG11202103073SA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CY1122801T1 (el) Σκευασματα τα οποια περιεχουν λινακλοτιδη για στοματικη χορηγηση
CY1123597T1 (el) Σκευασματα ινσουλινης για γρηγορη προσληψη
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
WO2012054500A3 (en) Compositions for drug administration
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
MX2021003574A (es) Composiciones y metodos para mejorar la entrega, tolerabilidad y eficacia de los peptidos y macrociclicos cationicos.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
JP2016516023A5 (es)
MX361590B (es) Suministro topico de composiciones para la piel que tienen ph bajo.
NZ534919A (en) Bioactive keratin peptides
WO2016042163A3 (en) Ophthalmic drug compositions
AR068816A1 (es) Composiciones de brimonidina mejorada para el tratamiento del eritema
BR112015011179A2 (pt) composições aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas
MX2010002409A (es) Composiciones y metodos para la distribucion de farmacos escasamente solubles.
NZ700182A (en) Parenteral formulations for administering macrolide antibiotics
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
EA201491212A1 (ru) Увлажняющая композиция, включающая аминопептидную смесь
MY181181A (en) Fgf21 derivatives and uses thereof
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
MY190257A (en) Optimised subcutaneous therapeutic agents
PH12020551500A1 (en) Viscosity reduction of highly concentrated protein formulations
JOP20210284A1 (ar) الإعطاء غير المتجانس للقاحات تاو
UA114298C2 (uk) Пептид торк та вакцина, що його містить
JP2016527292A5 (es)